 |
|
HLA-A2, A3-restricted FGF-5 peptides/Montanide ISA-51 vaccine
A peptide vaccine comprised of synthetic HLA-A2- and HLA-A3-binding peptides, derived from amino acid sequences of fibroblast growth factor-5 (FGF-5), combined with the adjuvant Montanide ISA-51 with potential antineoplastic activity. HLA-A2, A3-restricted FGF-5 peptides contain motifs recognized by the MHC class I molecules HLA-A2 and HLA-A3 and may stimulate a cytotoxic T-cell response against tumor cells that overexpress FGF-5. Montanide ISA-51 (also known as incomplete Freund's adjuvant or IFA), a stabilized water-in-oil emulsion adjuvant containing mineral oil with mannide oleate added as a surfactant, non-specifically stimulates cell-mediated immune responses to antigens. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
| Abbreviation: | | HLA-A2A3-FGF5-ISA51 | | |
| Previous: | HLA-A*2402-restricted URLC10-TTK-KOC1 multipeptide vaccine, HLA-A*2402-restricted URLC10-TTK-VEGFR1-VEGFR2 multipeptide vaccine, HLA-A*2402-restricted VEGFR1 peptide vaccine, HLA-A*2404-restricted RNF43-TOMM34-VEGFR1-VEGFR2 multipeptide vaccine, HLA-A1, A2, B35-restricted survivin peptides/Montanide ISA-51 vaccine | | Next: | Hodgkin's antigens-GM-CSF-expressing cell vaccine, HPPH, HPV 16 E7:86-93 peptide vaccine, HPV DNA plasmids therapeutic vaccine VGX-3100, HPV L1 VLP vaccine V504 |
|
|
